Dsi RNPs exhibit the selective and efficient intracellular delivery to the FR-positive KB-V1 cancer cells, while lowering the cellular uptake on the FR-negative cells, and therefore this distinct ability may lower the risk of severe adverse side effects, expected from the exceptionally increased cytotoxicity of siRNA-Dox combination. Here, P4HB is linked to cancer.